High-flow Nasal Cannula Oxygenation Revisited in COVID-19

Login or register to view PDF.
Creative Commons Licence
 
Disclosure
The authors have no conflicts of interest to declare.
Correspondence
Aniket S Rali, 7200 Cambridge St, A 10.189, BCM 903, Houston, TX 77030, US. E: aniketrali@gmail.com
Received date
10 April 2020
Accepted date
11 April 2020
DOI
https://doi.org/10.15420/cfr.2020.06
Open access
This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Dear Editor,

As of 31 March 2020, the Centers for Disease Control has reported a total of 163,593 confirmed coronavirus disease 2019 (COVID-19) cases and 2,860 COVID-19-related deaths in the US. According to several public health predictive models, these numbers are expected to continue to rise in the upcoming weeks, leading to a nationwide shortage of hospital beds and especially intensive care unit (ICU) beds. Owing to its predominantly respiratory manifestations, including acute respiratory distress syndrome (ARDS), one of the treatment modalities that is expected to run short is mechanical ventilators.

A case series of 138 COVID-19 patients from Wuhan, China showed that a total of 36 (26%) patients required ICU level care, of whom 22 (61%) developed ARDS and 17 (47.2%) required invasive mechanical ventilation.1 Other retrospective analyses have reported similarly that 20–31% of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients develop ARDS and require ICU care.2–4 Therefore, it is critical that we explore the utility and safety of other forms of respiratory support devices, including high-flow nasal cannula oxygenation (HFNCO) in the treatment of acute respiratory failure. In the above mentioned case series from China, 4 (11%) of the patients admitted to the ICU were successfully treated with HFNCO (Figure 1).1 Similarly, in other case series of 191 COVID-19 patients, 41 (21%) were treated with HFNCO (33 in ICU and 8 in non-ICU).4

We present a case of a SARS-CoV-2-positive patient with acute respiratory failure who was successfully treated with HFNCO. We also discuss the mechanisms of action, clinical effects, and available literature on the efficacy and safety of HFNCO, including the risk of aerosolising SARS-CoV-2 particles.

Case Presentation

A 51-year-old man presented to the emergency department (ED) with a 1-week history of worsening dyspnoea, fevers and non-productive cough in light of negative influenza testing at his primary care physician’s office. The patient had no travel history, but reported contact with international clients through his work.

His vital signs at the time of presentation were oral temperature of 99.7°C, heart rate of 105 BPM, respiratory rate of 35, blood pressure of 113/99 mmHg and oxygen saturation of 80% of room air. His physical examination was significant for respiratory distress, with use of accessory muscles and crackles in bilateral lung bases upon auscultation.

Chest X-ray showed bilateral multifocal hazy interstitial opacities (Figure 2). Respiratory viral panel, including influenza, was negative, but a SARS-CoV-2 polymerase chain reaction test that was sent while the patient was in the ED returned positive on day 4.

The patient was initially admitted to the progressive care unit under droplet and contact precautions pending SARS-CoV-2 test results, and ceftriaxone and azithromycin were initiated for presumed community-acquired pneumonia. On day 3, his hypoxic respiratory failure worsened, requiring high-flow nasal cannula at 40 l/min and 90% fractional inspired oxygen, (FiO2) and he was transferred to the medical ICU. The infectious diseases team was consulted and the patient commenced a 5-day course of lopinavir/ritonavir and hydroxychloroquine once the SARS-CoV-2 test was confirmed to be positive. Over the next 5 days, the patient was gradually weaned to room air. When he was haemodynamically stable, he was discharged with instructions to continue self-isolation at home for 14 additional days.

Discussion

Our report discusses a COVID-19 patient who presented with acute respiratory failure with moderate ARDS, in whom endotracheal intubation was prevented; the patient was successfully treated on HFNCO. The physiological benefits of HFNCO are improved oxygenation, decreased anatomical dead space, decreased metabolic demand of breathing, decreased production of carbon dioxide, superior comfort and improved work of breathing, positive nasopharyngeal and tracheal airway pressure and better secretion clearance.

First, the most important clinical benefit of HFNCO is that of efficient supplemental oxygen delivery. HFNCO therapy generates a flow-dependent FiO2.5 HFNCO therapy is able to maintain a high FiO2 by delivering flows higher than the spontaneous inspiratory demand, thus minimising room-air entrainment. In order to maximise the benefit of HFNCO, the flow rate must be titrated to match the patient’s inspiratory demand and severity of respiratory distress.

Second, HFNCO is also able to decrease anatomic dead space by washing CO2 out of the upper airways. Reduction in anatomic dead space then leads to improved work of breathing and lower respiratory rates. Mauri et al. demonstrated this effect in their study of hypoxemic patients with arterial partial pressure of oxygen to FiO2 ratios <300, where high-flow nasal cannula set at 40 l/min significantly reduced work of breathing and respiratory metabolic demand compared with oxygen delivered by face mask at 12 l/min.6 Therefore, patients with hypercarbia, in addition to hypoxaemia, gain benefit from HFNCO, not only through reduction in anatomic dead space but also through reduced CO2 production via lowered metabolic demand.

High-flow Nasal Cannula Oxygenation Device

Open in new tab
Open ppt

Chest X-ray Showing Diffuse Bilateral Ground Glass Opacities

Open in new tab
Open ppt

Third, HFNCO further reduces the work of breathing by optimally conditioning the delivered gas by warming and humidifying it to physiological conditions. This spares the body the energy cost of warming and humidifying inspired gas. Warm humid gas is also associated with better conductance and pulmonary compliance compared to dry and cooler gas. It also improves mucociliary function, thereby facilitating secretion clearance, decreasing risk of atelectasis and improving the ventilation/perfusion ratio and oxygenation.

Finally, HFNCO generates low-level positive pressure, which increases lung volumes and improves gas exchange. While alveolar recruitment results from the positive airway pressure, the magnitude of this effect is variable, and its clinical significance remains somewhat controversial. However, studies have estimated the positive pressure delivered through HFNCO to equal roughly 1 mm H2O for every 10 l of flow.7,8 In order to maximise the above-mentioned benefits of HFNCO, it is imperative to maintain the flow at the highest tolerated by the patient, usually at least 30–40 l/minute.

One potential concern that has been raised about the use of HFNCO in COVID-19 patients is that it could aerosolise the respiratory tract pathogen. Using evidence from several recently published studies, the WHO concluded that HFNCO does not create widespread dispersion of exhaled air, and therefore, should be associated with low risk of transmission of respiratory viruses.9 They do recommend wearing a standard medical face mask if a medical provider is within 2 m of the patient. However, a newer study showed that the distance of droplet dispersion from coughing increases by an average of 0.42 m with high-flow nasal cannula, and travelled further than the WHO-recommended 2-m safe exclusion zone.10 Based on this evidence, at our institution we ensure that COVID-19 patients on HFNCO are at the least in single-occupancy rooms with either negative pressure or high-efficiency particulate air filtration systems, and that all our healthcare workers caring for those patients wear full airborne personal protective equipment (i.e. N95 masks or equivalent, gown, gloves, goggles, hair covers and face shields).

Conclusion

HFNCO is an effective treatment modality for COVID-19-associated acute respiratory failure. Particularly in patients with mild to moderate ARDS and in negative pressure rooms, it could be a viable initial alternative to mechanical ventilation.

References
  1. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; epub ahead of press.
    Crossref | PubMed
  2. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13.
    Crossref | PubMed
  3. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020;368:m606.
    Crossref | PubMed
  4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.
    Crossref | PubMed
  5. Sztrymf B, Messika J, Bertrand F, et al. Beneficial effects of humidified high flow nasal oxygen in critical care patients: a prospective pilot study. Intensive Care Med 2011;37:1780–6.
    Crossref | PubMed
  6. Mauri T, Turrini C, Eronia N, et al. Physiologic effects of high-flow nasal cannula in acute hypoxemic respiratory failure. Am J Respir Crit Care Med 2017;195:1207–15.
    Crossref | PubMed
  7. Parke RL, Eccleston ML, McGuinness SP. The effects of flow on airway pressure during nasal high-flow oxygen therapy. Respir Care 2011;56:1151–5.
    Crossref | PubMed
  8. Parke RL, McGuinness SP. Pressures delivered by nasal high flow oxygen during all phases of the respiratory cycle. Respir Care 2013;58:1621–4.
    Crossref | PubMed
  9. WHO. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance. Geneva: WHO, 2020. https://www.who.int/publications-detail/clinical-management-of-severe-ac...(ncov)-infection-is-suspected (accessed 13 April 2020).
  10. Loh NW, Tan Y, Taculod J, et al. The impact of high-flow nasal cannula (HFNC) on coughing distance: implications on its use during the novel coronavirus disease outbreak. Can J Anaesth 2020; epub ahead of press.
    Crossref | PubMed